Publications by authors named "A Ittel"
Article Synopsis
- Elderly AML patients (60-75 years) with poor-risk cytogenetics typically have poor outcomes with intensive chemotherapy, but the effectiveness of Venetoclax (VEN) combined with other treatments is being studied.
- A study at Institut Paoli Calmettes involved comparing 26 patients treated with VEN to a historical cohort of 90 patients treated with intensive chemotherapy, focusing on treatment response and overall survival rates.
- The findings suggested that VEN showed promising results, with a 69% composite response rate and a median overall survival of 7.9 months, making it a potential alternative to intensive chemotherapy for high-risk elderly patients.
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML.
View Article and Find Full Text PDFObjectives: To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML).
Methods: We retrospectively analysed R/R AML patients treated with VEN-AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021.